{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:04:03Z","timestamp":1777878243315,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>Belantamab mafodotin (belamaf) is a first-in-class anti-B-cell maturation antigen (BCMA) antibody\u2013drug conjugate (ADC) that recently gained regulatory approval for the treatment of relapsed and\/or refractory multiple myeloma (RRMM) patients who have received at least four prior therapies including an anti-CD38 monoclonal antibody (mAb), a proteasome inhibitor (PI), and an immunomodulatory drug (IMiD). As the first BCMA-targeted therapy to be approved in multiple myeloma along with its \u201coff-the-shelf\u201d outpatient administration, belamaf addresses a significant unmet need in RRMM that is refractory to IMiD, PI, and anti-CD38 mAb therapy, otherwise known as triple-class refractory myeloma. Belamaf is also associated with frequent corneal ocular adverse events, which represents a unique toxicity in multiple myeloma therapeutics, and its administration requires a multidisciplinary approach with oncologists and eye care specialists to safely and effectively manage patients on belamaf therapy. In this review, we discuss the preclinical and clinical data leading to the regulatory approval of belamaf, the monitoring and mitigation strategies of corneal ocular adverse events, and its current and future role in the RRMM treatment landscape.<\/jats:p>","DOI":"10.1177\/2040620720979813","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T04:55:39Z","timestamp":1607921739000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["The role of belantamab mafodotin for patients with relapsed and\/or refractory multiple myeloma"],"prefix":"10.1177","volume":"11","author":[{"given":"Melody R.","family":"Becnel","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-3292","authenticated-orcid":false,"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX, 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"bibr1-2040620720979813","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Program https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html (2020, accessed 1 September 2020)."},{"key":"bibr2-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"bibr3-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15394"},{"key":"bibr4-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"bibr5-2040620720979813","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S174640"},{"key":"bibr6-2040620720979813","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123924"},{"key":"bibr7-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"bibr8-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0734-z"},{"key":"bibr9-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x"},{"key":"bibr10-2040620720979813","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.77"},{"key":"bibr11-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088"},{"key":"bibr12-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14145"},{"key":"bibr13-2040620720979813","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155192"},{"key":"bibr14-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X"},{"key":"bibr15-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6"},{"key":"bibr16-2040620720979813","unstructured":"de Oca RM, Bhattacharya S, Vitali N, et al. The anti-BCMA antibody-drug conjugate GSK2857916 drives immunogenic cell death and immune-mediated anti-tumor responses, and in combination with an OX40 agonist potentiates in vivo activity. Presented at 24th Congress of the European Hematology Association Annual Meeting, 13-16 June 2019, Amsterdam, The Netherlands. Abstract PF558."},{"key":"bibr17-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"bibr18-2040620720979813","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1200\/JCO.2020.38.15_suppl.8536","volume":"38","author":"Lonial S","year":"2020","journal-title":"J Clin Oncol"},{"key":"bibr19-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8502"},{"key":"bibr20-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3202"},{"key":"bibr21-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-020-00280-8."},{"key":"bibr22-2040620720979813","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.235937"},{"key":"bibr23-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14429"},{"key":"bibr24-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(20)30949-6"},{"key":"bibr25-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"bibr26-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"bibr27-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"bibr28-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12325"},{"key":"bibr29-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1952-5"},{"key":"bibr30-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.05.001"},{"key":"bibr31-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"bibr32-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121731"},{"key":"bibr33-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122895"},{"key":"bibr34-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.100"},{"key":"bibr35-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050"},{"key":"bibr36-2040620720979813","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8519"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620720979813","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2040620720979813","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620720979813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:15:13Z","timestamp":1777590913000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2040620720979813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":36,"alternative-id":["10.1177\/2040620720979813"],"URL":"https:\/\/doi.org\/10.1177\/2040620720979813","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"2040620720979813"}}